![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Array Biopharma Retracts Its New Drug Application For Binimetinib Monotherapy
Array Biopharma Retracts Its New Drug Application For Binimetinib Monotherapy
March 24, 2017
Array Biopharma has withdrawn its new drug application for binimetinib monotherapy for the treatment of NRAS-mutant melanoma, a rare, mutation-driven subset of skin cancer.
Array concluded from a meeting with the FDA that the clinical benefit demonstrated in the phase 3 clinical trial would not be found sufficient to support approval of the NDA.
The company said the withdrawal will not impact the planned phase 3 Columbus trial NDA of binimetinib, in combination with encorafenib, for the treatment of BRAF-mutant melanoma, which remains on track for mid-2017.
NRAS mutations are present in approximately 20 percent of the estimated 10,000 annual cases of metastatic melanoma in the United States.
Upcoming Events
-
21Oct